 |
| CrossRef Text and Data Mining |
| Result of CrossRef Text and Data Mining Search is the related articles with entitled article. If you click link1 or link2 you will be able to reach the full text site of selected articles; however, some links do not show the full text immediately at now. If you click CrossRef Text and Data Mining Download icon, you will be able to get whole list of articles from literature included in CrossRef Text and Data Mining. |
| Cardiovascular Safety of SGLT2 Inhibitors Compared to DPP4 Inhibitors and Sulfonylureas as the Second-Line of Therapy in T2DM Using Large, Real-World Clinical Data in Korea |
| Kyuho Kim, Sung Hee Choi |
|
Diabetes Metab J. 2021;45(4):502-504. Published online July 30, 2021 DOI: https://doi.org/10.4093/dmj.2021.0158 |
|
Cardiovascular Safety of SGLT2 Inhibitors Compared to DPP4 Inhibitors and Sulfonylureas as the Second-Line of Therapy in T2DM Using Large, Real-World Clinical Data in Korea Diabetes & Metabolism Journal. 2021;45(4):502-504  SGLT2 inhibitors cost effective versus sulfonylureas in T2DM PharmacoEconomics & Outcomes News. 2019;842(1):29-29 PDB7 DIABETIC COMPLICATIONS ASSOCIATED WITH SGLT2 AND DPP4 INHIBITORS: A REAL-WORLD APPROACH Value in Health. 2019;22:S141 The efficacy and safety of DPP4 inhibitors compared to sulfonylureas as add-on therapy to metformin in patients with Type 2 diabetes: A systematic review and meta-analysis Diabetes Research and Clinical Practice. 2015;109(2):378-388 393-P: SGLT2 Inhibitors Reduce Cardiovascular and Renal Risks Compared with GLP-1 Receptor Agonists and DPP4 Inhibitors in Patients with Diabetic Kidney Disease: A Systematic Review and Network Meta-analysis Diabetes. 2022;71(Supplement_1): Generalizability of Cardiovascular Safety Trials on SGLT2 Inhibitors to the Real World: Implications for Clinical Practice Advances in Therapy. 2019;36(10):2895-2909 1211-P: Real-World Use of SGLT2 Inhibitors in a Large U.S. Safety-Net Health System Diabetes. 2020;69(Supplement_1): Efficacy and Safety of Regorafenib with or without PD-1 Inhibitors as Second-Line Therapy for Advanced Hepatocellular Carcinoma in Real-World Clinical Practice OncoTargets and Therapy. 2022;Volume 15:1079-1094 Clinical and Safety Outcomes With GLP-1 Receptor Agonists and SGLT2 Inhibitors in Type 1 Diabetes: A Real-World Study The Journal of Clinical Endocrinology & Metabolism. 2022; Comparison between SGLT2 inhibitors and DPP4 inhibitors added to insulin therapy in type 2 diabetes: a systematic review with indirect comparison meta-analysis Diabetes/Metabolism Research and Reviews. 2016;33(1):e2818 |
